Clinical studies have also revealed significant differences in MS4A8B protein expression across benign prostate tissue, adjacent prostate cancer tissue, prostatic intraepithelial neoplasia, prostate carcinoma in situ, and metastatic prostate cancer lymph nodes. This evidence concerns the gene MS4A8 and prostate cancer.